滚动资讯
FierceBiotechWith 3 acquisitions to digest, Gilead shifts focus from M&A to pipeline that has 'never been stronger'Endpoints NewsEuropean VC Jeito gets $1.2B to help private biotechs control their 'destiny'Endpoints NewsDid Eli Lilly just strike another gold mine?Endpoints NewsWhat’s familiar in health tech’s Q1 funding totalsEndpoints NewsStudy suggests $35 monthly insulin cap has increased patient accessPromega BlogNew Study Suggests Cancer Research Has an Age ProblemEndpoints NewsWhite House adds AbbVie's Humira to TrumpRx alongside cheaper biosimilarsBioPharma DiveTerns rebuffed a higher bid before selling to MerckFierceBiotechLilly pays AC Immune $12.5M to expand Alzheimer’s collab as asset draws closer to clinicFierceBiotechLongtime Hologic CEO Steve MacMillan to retire as $18.3B deal closesFierceBiotechOwlet CEO exits suddenly, co-founder returns to the nestFierceBiotechE2 lands $80M series C for next gen thrombectomy treatment
Roche Media 2026年2月2日

罗氏以17亿美元收购赛诺基因药物，继续RNA领域回归之路——Fierce Biotech

罗氏以17亿美元收购赛诺基因药物，继续RNA领域回归之路——Fierce Biotech

原文
暂时没有全文，请查看原始来源。

目录

59 全部